Delhi High Court: Teva Pharma Vs Union of India Tax Judgment Victory

• The Delhi High Court ruled that a ₹1,851 crore payment from the erstwhile Ranbaxy Laboratories to Teva Israel is not taxable in India.
• The court stated that payments from Indian residents to non-residents are not automatically taxable unless they fall under specific deeming provisions of Section 5(2)(b) or Section 9 of the Income Tax Act.
• Justices Dinesh Mehta and Vinod Kumar delivered the judgment on September 15, confirming the absence of jurisdictional foundation for a Section 148 notice.
• The payment stemmed from a settlement agreement concerning generic Atorvastatin, for which the erstwhile Ranbaxy had 180-day US market exclusivity.
• A refund of tax already deducted by the erstwhile Ranbaxy is subject to Teva USA and Teva Israel furnishing court-directed guarantees.

The core of the Delhi High Court's finding is that a payment made by an Indian resident to a non-resident entity does not, by itself, constitute income accruing or arising in India for tax purposes.

The Delhi High Court has delivered a significant ruling in favor of Israeli pharmaceutical giant Teva Israel, determining that a substantial payment of ₹1,851 crore received from the erstwhile Ranbaxy Laboratories is not subject to taxation in India. This decision, stemming from the Teva Pharma Vs Union of India tax judgment, overturns a prior tax demand and clarifies the conditions under which payments from Indian entities to foreign companies become taxable within the country's jurisdiction. The judgment was pronounced on September 15 by a bench comprising Justices Dinesh Mehta and Vinod Kumar.

The core of the Delhi High Court's finding is that a payment made by an Indian resident to a non-resident entity does not, by itself, constitute income accruing or arising in India for tax purposes. The court emphasized that for such income to be taxable, it must specifically fall under the deeming provisions outlined in Section 5(2)(b) or Section 9 of the Income Tax Act of 1961. In the absence of these specific conditions being met, the foundational basis for issuing a notice under Section 148 of the Act, which initiates reassessment proceedings, collapses.

The court's pronouncement provides crucial clarity on the taxability of foreign entity payments in India, particularly concerning settlement agreements. The bench explicitly stated that the transaction between the erstwhile Ranbaxy and Teva Israel did not align with the criteria set forth in either Section 5(2)(b) or Section 9 of the Income Tax Act. Section 5(2)(b) deals with the scope of total income for non-residents, while Section 9 outlines specific types of income that are deemed to accrue or arise in India, even if the actual receipt occurs outside the country.

By ruling that the Ranbaxy Teva settlement taxability did not trigger these deeming provisions, the Delhi High Court non-resident income tax decision reinforces the principle that Indian tax authorities cannot automatically levy tax on payments merely because they originate from an Indian company. This Teva Israel tax victory underscores the necessity for tax authorities to demonstrate a clear nexus under the statutory provisions before asserting jurisdiction over a non-resident's income.

The substantial payment at the heart of this dispute originated from a settlement agreement related to the cholesterol-lowering medicine Atorvastatin, widely known by Pfizer's brand name Lipitor. The erstwhile Ranbaxy had been the first company to seek and obtain US regulatory approval for a generic version of this drug. This pioneering status entitled Ranbaxy to a significant 180-day exclusivity period, during which no other generic drug applicant could receive approval for the same medicine in the United States.

Despite this entitlement, there was initial uncertainty surrounding Ranbaxy's ability to secure final approval for its generic Atorvastatin. This complex scenario ultimately led to the settlement agreement between the erstwhile Ranbaxy Laboratories and Teva Israel, which included the ₹1,851 crore payment now deemed non-taxable in India by the High Court.

It was noted during the proceedings that the erstwhile Ranbaxy had already deducted tax at source before remitting the payment to Teva Israel. Following the Delhi High Court's favorable ruling, the refund of this deducted amount to Teva is contingent upon specific conditions. Both Teva USA and Teva Israel are required to furnish guarantees as directed by the Court. This stipulation ensures compliance and provides a safeguard while the refund process is executed.

This outcome provides a significant precedent for other foreign entities receiving payments from Indian residents, particularly in the context of complex commercial settlements. The Teva Pharma Vs Union of India tax judgment clarifies that the source of payment alone is insufficient to establish taxability in India, emphasizing the critical role of specific deeming provisions under the Income Tax Act.

This ruling clarifies that payments from Indian residents to non-residents are not automatically taxable in India unless they fall under specific deeming provisions of the Income Tax Act. Lawyers and compliance officers should review cross-border payment structures, particularly for settlement agreements, to ensure they do not inadvertently trigger Indian tax liability for foreign entities, and understand the specific conditions under Sections 5(2)(b) and 9.

Source: Original reporting via Bar and Bench